151
|
Zehentner B, Broderson L, Stephenson C, Cutler J, de Baca M, Menssen A, Hammock K, Johnson K, Hartmann L, Loken M, Wells D. 169 SNP/CGH MICROARRAY ANALYSIS IN MDS: CORRELATION WITH CONVENTIONAL CYTOGENETICS, FISH AND FLOW CYTOMETRIC FINDINGS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30170-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
152
|
Bobbs M, Frazer T, Humphrey S, Bayer M, Wilson B, Olasz E, Holland K, Johnson K, Kuzminski J. Developing a low cost, mutually beneficial teledermatology
collaboration. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
153
|
Chang W, Wu Y, Johnson K, Loecher M, Wieben O, Edjlali M, Oppenheim C, Roca P, Hald J, Aagaard-Kienitz B, Niemann D, Mistretta C, Turski P. Fast contrast-enhanced 4D MRA and 4D flow MRI using constrained reconstruction (HYPRFlow): potential applications for brain arteriovenous malformations. AJNR Am J Neuroradiol 2015; 36:1049-55. [PMID: 25698624 DOI: 10.3174/ajnr.a4245] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Accepted: 09/29/2014] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE HYPRFlow is a novel imaging strategy that provides fast, high-resolution contrast-enhanced time-resolved images and measurement of the velocity of the entire cerebrovascular system. Our hypothesis was that the images obtained with this strategy are of adequate diagnostic image quality to delineate the major components of AVMs. MATERIALS AND METHODS HYPRFlow and 3D TOF scans were obtained in 21 patients with AVMs with correlative DSA examinations in 14 patients. The examinations were scored for image quality and graded by using the Spetzler-Martin criteria. Mean arterial transit time and overlap integrals were calculated from the dynamic image data. Volume flow rates in normal arteries and AVM feeding arteries were measured from the phase contrast data. RESULTS HYPRFlow was equivalent to 3D-TOF in delineating normal arterial anatomy, arterial feeders, and nidus size and was concordant with DSA for AVM grading and venous drainage in 13 of the 14 examinations. Mean arterial transit time on the AVM side was 0.49 seconds, and on the normal contralateral side, 2.53 seconds with P < .001. Across all 21 subjects, the mean arterial volume flow rate in the M1 segment ipsilateral to the AVM was 4.07 ± 3.04 mL/s; on the contralateral M1 segment, it was 2.09 ± 0.64 mL/s. The mean volume flow rate in the largest feeding artery to the AVM was 3.86 ± 2.74 mL/s. CONCLUSIONS HYPRFlow provides an alternative approach to the MRA evaluation of AVMs, with the advantages of increased coverage, 0.75-second temporal resolution, 0.68-mm isotropic spatial resolution, and quantitative measurement of flow in 6 minutes.
Collapse
Affiliation(s)
- W Chang
- From the Department of Radiology (W.C.), University of California, Los Angeles, Los Angeles, California
| | - Y Wu
- Medical Physics (Y.W., K.J., M.L., O.W., C.M.), University of Wisconsin School of Medicine, Madison, Wisconsin
| | - K Johnson
- Medical Physics (Y.W., K.J., M.L., O.W., C.M.), University of Wisconsin School of Medicine, Madison, Wisconsin
| | - M Loecher
- Medical Physics (Y.W., K.J., M.L., O.W., C.M.), University of Wisconsin School of Medicine, Madison, Wisconsin
| | - O Wieben
- Medical Physics (Y.W., K.J., M.L., O.W., C.M.), University of Wisconsin School of Medicine, Madison, Wisconsin
| | - M Edjlali
- Department of Radiology (M.E., C.O., P.R.), Université Paris-Descartes, Paris, France
| | - C Oppenheim
- Department of Radiology (M.E., C.O., P.R.), Université Paris-Descartes, Paris, France
| | - P Roca
- Department of Radiology (M.E., C.O., P.R.), Université Paris-Descartes, Paris, France
| | - J Hald
- Department of Radiology (J.H.), Rikshospitalet, Oslo, Norway
| | | | | | - C Mistretta
- Medical Physics (Y.W., K.J., M.L., O.W., C.M.), University of Wisconsin School of Medicine, Madison, Wisconsin
| | - P Turski
- Departments of Radiology (B.A.-K., P.T.)
| |
Collapse
|
154
|
Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ 2015; 18:1092-101. [PMID: 26368787 DOI: 10.3111/13696998.2015.1078339] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To estimate, from a US payer perspective, the cost offsets of treating gram positive acute bacterial skin and skin-structure infections (ABSSSI) with varied hospital length of stay (LOS) followed by outpatient care, as well as the cost implications of avoiding hospital admission. METHODS Economic drivers of care were estimated using a literature-based economic model incorporating inpatient and outpatient components. The model incorporated equal efficacy, adverse events (AE), resource use, and costs from literature. Costs of once- and twice-daily outpatient infusions to achieve a 14-day treatment were analyzed. Sensitivity analyses were performed. Costs were adjusted to 2015 US$. RESULTS Total non-drug medical cost for treatment of ABSSSI entirely in the outpatient setting to avoid hospital admission was the lowest among all scenarios and ranged from $4039-$4924. Total non-drug cost for ABSSSI treated in the inpatient setting ranged from $9813 (3 days LOS) to $18,014 (7 days LOS). Inpatient vs outpatient cost breakdown was: 3 days inpatient ($6657)/11 days outpatient ($3156-$3877); 7 days inpatient ($15,017)/7 days outpatient ($2495-$2997). Sensitivity analyses revealed a key outpatient cost driver to be peripherally inserted central catheter (PICC) costs (average per patient cost of $873 for placement and $205 for complications). LIMITATIONS Drug and indirect costs were excluded and resource use was not differentiated by ABSSSI type. It was assumed that successful ABSSSI treatment takes up to 14 days per the product labels, and that once-daily and twice-daily antibiotics have equal efficacy. CONCLUSION Shifting ABSSSI care to outpatient settings may result in medical cost savings greater than 53%. Typical outpatient scenarios represent 14-37% of total medical cost, with PICC accounting for 28-43% of the outpatient burden. The value of new ABSSSI therapies will be driven by eliminating the need for PICC line, reducing length of stay and the ability to completely avoid a hospital stay.
Collapse
Affiliation(s)
- V Ektare
- a Pharmerit International , Bethesda , MD , USA
| | | | - M Xue
- a Pharmerit International , Bethesda , MD , USA
| | - M Dunne
- b Durata Therapeutics , Chicago , IL , USA
| | - K Johnson
- b Durata Therapeutics , Chicago , IL , USA
| | - J Stephens
- a Pharmerit International , Bethesda , MD , USA
| |
Collapse
|
155
|
Johnson K, Lowe B. Readmissions following an elevated high-sensitive troponin with non-obstructive coronary arteries and no evidence of late gadolinium enhancement on cardiac MRI. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.04.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
156
|
Chandrala P, Johnson K, Hallani H. A case of a thrombus trapped in a patent foramen ovale. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.06.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
157
|
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis 2014; 1:181-202. [PMID: 26478889 PMCID: PMC4606938 DOI: 10.14283/jpad.2014.32] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Alzheimer's disease (AD) is a slowly progressing non-linear dynamic brain disease in which pathophysiological abnormalities, detectable in vivo by biological markers, precede overt clinical symptoms by many years to decades. Use of these biomarkers for the detection of early and preclinical AD has become of central importance following publication of two international expert working group's revised criteria for the diagnosis of AD dementia, mild cognitive impairment (MCI) due to AD, prodromal AD and preclinical AD. As a consequence of matured research evidence six AD biomarkers are sufficiently validated and partly qualified to be incorporated into operationalized clinical diagnostic criteria and use in primary and secondary prevention trials. These biomarkers fall into two molecular categories: biomarkers of amyloid-beta (Aβ) deposition and plaque formation as well as of tau-protein related hyperphosphorylation and neurodegeneration. Three of the six gold-standard ("core feasible) biomarkers are neuroimaging measures and three are cerebrospinal fluid (CSF) analytes. CSF Aβ1-42 (Aβ1-42), also expressed as Aβ1-42 : Aβ1-40 ratio, T-tau, and P-tau Thr181 & Thr231 proteins have proven diagnostic accuracy and risk enhancement in prodromal MCI and AD dementia. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow-up. Magnetic resonance imaging (MRI) at increasing field strength and resolution allows detecting the evolution of distinct types of structural and functional abnormality pattern throughout early to late AD stages. Anatomical or volumetric MRI is the most widely used technique and provides local and global measures of atrophy. The revised diagnostic criteria for "prodromal AD" and "mild cognitive impairment due to AD" include hippocampal atrophy (as the fourth validated biomarker), which is considered an indicator of regional neuronal injury. Advanced image analysis techniques generate automatic and reproducible measures both in regions of interest, such as the hippocampus and in an exploratory fashion, observer and hypothesis-indedendent, throughout the entire brain. Evolving modalities such as diffusion-tensor imaging (DTI) and advanced tractography as well as resting-state functional MRI provide useful additionally useful measures indicating the degree of fiber tract and neural network disintegration (structural, effective and functional connectivity) that may substantially contribute to early detection and the mapping of progression. These modalities require further standardization and validation. The use of molecular in vivo amyloid imaging agents (the fifth validated biomarker), such as the Pittsburgh Compound-B and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) (as the sixth validated biomarker) support the detection of early AD pathological processes and associated neurodegeneration. How to use, interpret, and disclose biomarker results drives the need for optimized standardization. Multimodal AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping fashion. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. AD biomarkers can be combined to increase accuracy or risk. A list of genetic risk factors is increasingly included in secondary prevention trials to stratify and select individuals at genetic risk of AD. Although most of these biomarker candidates are not yet qualified and approved by regulatory authorities for their intended use in drug trials, they are nonetheless applied in ongoing clinical studies for the following functions: (i) inclusion/exclusion criteria, (ii) patient stratification, (iii) evaluation of treatment effect, (iv) drug target engagement, and (v) safety. Moreover, novel promising hypothesis-driven, as well as exploratory biochemical, genetic, electrophysiological, and neuroimaging markers for use in clinical trials are being developed. The current state-of-the-art and future perspectives on both biological and neuroimaging derived biomarker discovery and development as well as the intended application in prevention trials is outlined in the present publication.
Collapse
Affiliation(s)
- E Cavedo
- Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Institut du Cerveau et de la Moelle épinière (ICM), UMR S 1127, Hôpital de la Pitié-Salpétrière Paris & CATI multicenter neuroimaging platform, France; Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio Fatebenefratelli Brescia, Italy
| | - S Lista
- AXA Research Fund & UPMC Chair; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| | - Z Khachaturian
- The Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020), Potomac, MD, USA
| | - P Aisen
- Department of Neurosciences, University of California San Diego, San Diego, CA, USA
| | - P Amouyel
- Inserm, U744, Lille, 59000, France; Université Lille 2, Lille, 59000, France; Institut Pasteur de Lille, Lille, 59000, France; Centre Hospitalier Régional Universitaire de Lille, Lille, 59000, France
| | - K Herholz
- Institute of Brain, Behaviour and Mental Health, University of Manchester, UK
| | - C R Jack
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - R Sperling
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - J Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health, 888 West Bonneville Avenue, Las Vegas, Nevada 89106, USA
| | - K Blennow
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
| | - S O'Bryant
- Department of Internal Medicine, Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - G B Frisoni
- IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva, Geneva, Switzerland
| | | | - M Kivipelto
- Karolinska Institutet Alzheimer Research Center, NVS, Stockholm, Sweden
| | - W Klunk
- Department of Psychiatry, University of Pittsburgh School of Medicine, USA; Department of Neurology, University of Pittsburgh School of Medicine, USA
| | - K Broich
- Federal Institute of Drugs and Medical Devices (BfArM), Bonn, Germany
| | - S Andrieu
- Inserm UMR1027, Université de Toulouse III Paul Sabatier, Toulouse, France; Public health department, CHU de Toulouse
| | - M Thiebaut de Schotten
- Natbrainlab, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, King's College London, London, UK; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (ICM), UMRS 1127 Paris, France; Inserm, U 1127, Paris, France; CNRS, UMR 7225, Paris, France
| | - J-F Mangin
- CEA UNATI, Neurospin, CEA Gif-sur-Yvette, France & CATI multicenter neuroimaging platform
| | - A A Lammertsma
- Department of Radiology & Nuclear Medicine, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
| | - K Johnson
- Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - S Teipel
- Department of Psychosomatic Medicine, University of Rostock, and DZNE, German Center for Neurodegenerative Diseases, Rostock, Germany
| | - A Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne Germany
| | - A Bokde
- Cognitive Systems Group, Discipline of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
| | - O Colliot
- Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France; Institut du Cerveau et de la Moelle épinière, ICM, Inserm, U1127, F-75013, Paris, France; CNRS, UMR 7225 ICM, 75013, Paris, France; Inria, Aramis project-team, Centre de Recherche Paris-Rocquencourt, France
| | - H Bakardjian
- Institute of Memory and Alzheimer's Disease (IM2A), Pitié-Salpétrière University Hospital, Paris, France; IHU-A-ICM - Paris Institute of Translational Neurosciences, Paris, France
| | - H Zetterberg
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; UCL Institute of Neurology, Queen Square, London, UK
| | - B Dubois
- Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| | - B Vellas
- Inserm UMR1027, University of Toulouse, Toulouse, France
| | - L S Schneider
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - H Hampel
- AXA Research Fund & UPMC Chair; Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) Hôpital de la Pitié-Salpétrière & Inserm U1127 Institut du Cerveau et de la Moelle épinière (ICM), Hôpital de la Pitié-Salpétrière Paris, France
| |
Collapse
|
158
|
Johnson K. ED-10 * ASSOCIATIONS BETWEEN MATERNAL AND INHERITED GENETIC VARIATION IN FOLATE METABOLISM GENES AND PEDIATRIC BRAIN TUMORS IN A HIGH RISK POPULATION: A PILOT STUDY. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou253.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
159
|
Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, Hou L, Chen DTW, Laje G, Johnson K, Lipska BK, Kleinman JE, Corrada-Bravo H, Detera-Wadleigh S, Munson PJ, McMahon FJ. RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry 2014; 19:1179-85. [PMID: 24393808 PMCID: PMC5560442 DOI: 10.1038/mp.2013.170] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Revised: 10/24/2013] [Accepted: 10/29/2013] [Indexed: 11/09/2022]
Abstract
RNA-sequencing (RNA-seq) is a powerful technique to investigate the complexity of gene expression in the human brain. We used RNA-seq to survey the brain transcriptome in high-quality postmortem dorsolateral prefrontal cortex from 11 individuals diagnosed with bipolar disorder (BD) and from 11 age- and gender-matched controls. Deep sequencing was performed, with over 350 million reads per specimen. At a false discovery rate of <5%, we detected five differentially expressed (DE) genes and 12 DE transcripts, most of which have not been previously implicated in BD. Among these, Prominin 1/CD133 and ATP-binding cassette-sub-family G-member2 (ABCG2) have important roles in neuroplasticity. We also show for the first time differential expression of long noncoding RNAs (lncRNAs) in BD. DE transcripts include those of serine/arginine-rich splicing factor 5 (SRSF5) and regulatory factor X4 (RFX4), which along with lncRNAs have a role in mammalian circadian rhythms. The DE genes were significantly enriched for several Gene Ontology categories. Of these, genes involved with GTPase binding were also enriched for BD-associated SNPs from previous genome-wide association studies, suggesting that differential expression of these genes is not simply a consequence of BD or its treatment. Many of these findings were replicated by microarray in an independent sample of 60 cases and controls. These results highlight common pathways for inherited and non-inherited influences on disease risk that may constitute good targets for novel therapies.
Collapse
Affiliation(s)
- N Akula
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - J Barb
- Mathematical and Statistical Computing Laboratory, Center for Information
Technology, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - X Jiang
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - JR Wendland
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - KH Choi
- Department of Psychiatry, Uniformed Services University of the Health
Sciences, Bethesda, MD, USA
| | - SK Sen
- Genetic Disease Research Branch, National Human Genome Research Institute,
National Institutes of Health, US Department of Health and Human Services, Bethesda, MD,
USA
| | - L Hou
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - DTW Chen
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - G Laje
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - K Johnson
- Bioinformatics Section, Information Technology & Bioinformatics
Program, Division of Intramural Research, National Institute of Neurological Disorders
& Stroke, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - BK Lipska
- Human Brain Collection Core, Division of Intramural Research Programs,
National Institute of Mental Health Intramural Research Program, National Institutes of
Health, US Department of Health and Human Services, Bethesda, MD, USA
| | - JE Kleinman
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus,
Baltimore, MD, USA
| | - H Corrada-Bravo
- Department of Computer Science, Institute for Advanced Computer Studies and
Center for Bioinformatics and Computational Biology, University of Maryland, College Park,
MD, USA
| | - S Detera-Wadleigh
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - PJ Munson
- Mathematical and Statistical Computing Laboratory, Center for Information
Technology, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| | - FJ McMahon
- Human Genetics Branch, National Institute of Mental Health Intramural
Research Program, National Institutes of Health, US Department of Health and Human Services,
Bethesda, MD, USA
| |
Collapse
|
160
|
Guadagnin E, Dastgir J, Yang L, Johnson K, Wang Q, Hu Y, Dillmann A, Cookson M, Bönnemann C. G.P.213. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
161
|
McDonald M, Stockdale C, Che W, Castaneda A, Johnson K, Lagneaux A, McConnell L, Hardy-Fairbanks A. Vaginal misoprostol versus concentrated oxytocin for midtrimester labor induction: a retrospective chart review. Contraception 2014. [DOI: 10.1016/j.contraception.2014.05.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
162
|
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry 2014; 19:1044-51. [PMID: 24614494 PMCID: PMC4195975 DOI: 10.1038/mp.2014.9] [Citation(s) in RCA: 144] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 11/19/2013] [Accepted: 12/16/2013] [Indexed: 12/18/2022]
Abstract
This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66 ± 1.47 vs -0.71 ± 1.09, P = 0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P < 0.05). Similar to MCI subjects, Aβ+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P<0.05), whereas Aβ+ AD patients showed greater declines in verbal fluency and the MMSE (P < 0.05). Aβ+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P<0.04), a global clinical assessment. Aβ+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET Aβ+ subjects show greater cognitive and global deterioration over a 3-year follow-up than Aβ- subjects do.
Collapse
Affiliation(s)
- P M Doraiswamy
- Duke University Medical Center, Durham, NC, USA,Professor of Psychiatry, Duke University, Room 3550, Duke South Hospital, 1000 Trent Drive, Duke University Medical Center, Durham, 27710, NC,USAE-mail:
| | - R A Sperling
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - K Johnson
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - E M Reiman
- Banner Alzheimer's Institute, Phoenix, AZ, USA
| | - T Z Wong
- Duke University Medical Center, Durham, NC, USA
| | - M N Sabbagh
- Banner-Sun Health Research Institute, Sun City, AZ, USA
| | | | - A S Fleisher
- Banner Alzheimer's Institute, Phoenix, AZ, USA,University of California, San Diego, CA, USA
| | - A Carpenter
- Avid Radiopharmaceuticals, Philadelphia, PA, USA
| | - A D Joshi
- Avid Radiopharmaceuticals, Philadelphia, PA, USA
| | - M Lu
- Avid Radiopharmaceuticals, Philadelphia, PA, USA
| | - M Grundman
- University of California, San Diego, CA, USA,Global R&D Partners, San Diego, CA, USA
| | - M A Mintun
- Avid Radiopharmaceuticals, Philadelphia, PA, USA
| | | | - M J Pontecorvo
- Avid Radiopharmaceuticals, Philadelphia, PA, USA,Avid Radiopharmaceuticals, 3711 Market Street, Philadelphia, PA, 19104, USA. E-mail:
| | | | | |
Collapse
|
163
|
Johnson K, Noschka E, Allen K, Tilbrook A, Ryan T, Franklin S. Effect of Head and Neck Position on Upper Airway Function in Standardbred Racehorses. Equine Vet J 2014. [DOI: 10.1111/evj.12267_67] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- K Johnson
- University of Adelaide; Roseworthy Australia
| | - E Noschka
- University of Adelaide; Roseworthy Australia
| | - K Allen
- University of Bristol; Bristol United Kingdom
| | - A Tilbrook
- University of Adelaide; Roseworthy Australia
| | - T Ryan
- Ryanracing; Roseworthy Australia
| | - S Franklin
- University of Adelaide; Roseworthy Australia
| |
Collapse
|
164
|
Pau S, Walton J, Mackie A, Hartfield DS, Johnson K, Ellsworth J. 162: Diagnosis and Treatment of Kawasaki Disease in a Paediatric Tertiary Care Centre: A Quality Review. Paediatr Child Health 2014. [DOI: 10.1093/pch/19.6.e35-158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
165
|
Adamson E, Gordon J, Johnson K, Fain S. SU-E-QI-11: Measurement of Renal Pyruvate-To-Lactate Exchange with Hyperpolarized 13C MRI. Med Phys 2014. [DOI: 10.1118/1.4888991] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
166
|
Gauthier S, Johnson K, Dubois B. Communicating the diagnosis of Alzheimer's disease: Dilemmas and perspectives. Neurobiol Aging 2014. [DOI: 10.1016/j.neurobiolaging.2014.01.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
167
|
Johnson K, Boucher HW. Editorial Commentary: Imminent Challenges: Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancy. Clin Infect Dis 2014; 58:1284-6. [DOI: 10.1093/cid/ciu056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
168
|
Johnson K, Signy J, Pemberton J, Cadogan J. Trastuzumab induced cardiotoxicity in Auckland. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.04.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
169
|
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, Rafii M, Robert P, Schneider LS, Siemers E, Sperling R, Tariot P, Touchon J, Weiner M, Andrieu S, Aisen P. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alzheimers Dis 2014; 1:110-116. [PMID: 29255837 DOI: 10.14283/jpad.2014.6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Successful therapeutic trials require well-targeted populations to demonstrate the effectiveness of a drug candidate. Most trials in the field of Alzheimer's disease (AD) have been conducted in patients with mild to moderate dementia. However, the advent of amyloid PET imaging has demonstrated that a significant proportion of individuals enrolled in such studies do not have evidence of brain amyloidosis and may in fact not have Alzheimer's disease. Further, dementia represents an advanced stage of neurodegeneration, perhaps too late for significant benefits of disease-modifying interventions. The successful development of effective disease-slowing therapies requires a study population selected in accordance with the mechanism of the specific intervention. An international task force of investigators from academia, industry, non-profit foundations, and regulatory agencies met in San Diego, California, USA, on November 13, 2013, to address issues related to screening and identification of clinical trial participants, and the ramifications of decisions made in this regard for drug development in AD and other dementias.
Collapse
Affiliation(s)
- B Vellas
- Professor Bruno Vellas, MD, PhD, Hôpital Casselardit, Gerontopole, UMR INSERM1027, 170 Avenue Casselardit, 31059 Toulouse Cedex 03, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
170
|
Mueller GA, Maleki SJ, Johnson K, Hurlburt BK, Cheng H, Ruan S, Nesbit JB, Pomés A, Edwards LL, Schorzman A, Deterding LJ, Park H, Tomer KB, London RE, Williams JG. Identification of Maillard reaction products on peanut allergens that influence binding to the receptor for advanced glycation end products. Allergy 2013; 68:1546-54. [PMID: 24266677 DOI: 10.1111/all.12261] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Recent immunological data demonstrated that dendritic cells preferentially recognize advanced glycation end product (AGE)-modified proteins, upregulate expression of the receptor for AGE (RAGE), and consequently bias the immune response toward allergy. METHODS Peanut extract was characterized by mass spectrometry (MS) to elucidate the specific residues and specific AGE modifications found in raw and roasted peanuts and on rAra h 1 that was artificially glycated by incubation with glucose or xylose. The binding of the RAGE-V1C1 domain to peanut allergens was assessed by PAGE and Western analysis with anti-Ara h 1, 2, and 3 antibodies. IgE binding to rAra h 1 was also assessed using the same methods. RESULTS AGE modifications were found on Ara h 1 and Ara h 3 in both raw and roasted peanut extract. No AGE modifications were found on Ara h 2. Mass spectrometry and Western blot analysis demonstrated that RAGE binds selectively to Ara h 1 and Ara h 3 derived from peanut extract, whereas the analysis failed to demonstrate Ara h 2 binding to RAGE. rAra h 1 with no AGE modifications did not bind RAGE; however, after AGE modification with xylose, rAra h 1 bound to RAGE. CONCLUSIONS AGE modifications to Ara h 1 and Ara h 3 can be found in both raw and roasted peanuts. Receptor for AGE was demonstrated to selectively interact with AGE-modified rAra h 1. If sensitization to peanut allergens occurs in dendritic cells via RAGE interactions, these cells are likely interacting with modified Ara h 1 and Ara h 3, but not Ara h 2.
Collapse
Affiliation(s)
- G. A. Mueller
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - S. J. Maleki
- US Department of Agriculture; Agricultural Research Service; Southern Regional Research Center; New Orleans LA USA
| | - K. Johnson
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - B. K. Hurlburt
- US Department of Agriculture; Agricultural Research Service; Southern Regional Research Center; New Orleans LA USA
| | - H. Cheng
- US Department of Agriculture; Agricultural Research Service; Southern Regional Research Center; New Orleans LA USA
| | - S. Ruan
- US Department of Agriculture; Agricultural Research Service; Southern Regional Research Center; New Orleans LA USA
| | - J. B. Nesbit
- US Department of Agriculture; Agricultural Research Service; Southern Regional Research Center; New Orleans LA USA
| | - A. Pomés
- Indoor Biotechnologies, Inc.; Charlottesville VA USA
| | - L. L. Edwards
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - A. Schorzman
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - L. J. Deterding
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - H. Park
- The Scripps Research Institute; Jupiter FL USA
| | - K. B. Tomer
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - R. E. London
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| | - J. G. Williams
- Laboratory of Structural Biology; National Institute of Environmental Health Sciences; Research Triangle Park NC USA
| |
Collapse
|
171
|
Parke E, Hart J, Baldock D, Barchard K, Etcoff L, Allen D, Stolberg P, Nardi N, Cohen J, Jones W, Loe S, Etcoff L, Delgaty L, Tan A, Bunner M, Delgaty L, Tan A, Bunner M, Tan A, Delgaty L, Bunner M, Tan A, Delgaty L, Bunner M, Goodman G, Kim W, Nolty A, Marion S, Davis A, Finch W, Piehl J, Moss L, Nogin R, Dean R, Davis J, Lindstrom W, Poon M, Fonseca F, Bure-Reyes A, Stewart J, Golden C, Fonseca F, Bure-Reyes A, Stewart J, Golden C, Fields K, Hill B, Corley E, Russ K, Boettcher A, Musso M, Rohling M, Rowden A, Downing K, Benners M, Miller D, Maricle D, Dugbartey T, Anum A, Anderson J, Daniel M, Hoskins L, Gillis K, Khen S, Carter K, Ayers C, Neeland I, Cullum M, Weiner M, Rossetti H, Buddin W, Mahal S, Schroeder R, Baade L, Macaluso M, Phelps K, Evans C, Clark J, Vickery C, Chow J, Stokic D, Phelps K, Evans C, Watson S, Odom R, Clark J, Clark J, Odom R, Evans C, Vickery C, Thompson J, Noggle C, Kane C, Kecala N, Lane E, Raymond M, Woods S, Iudicello J, Dawson M, Ghias A, Choe M, Yudovin S, McArthur D, Asarnow R, Giza C, Babikian T, Tun S, O'Neil M, Ensley M, Storzbach D, Ellis R, O'Neil M, Carlson K, Storzbach D, Brenner L, Freeman M, Quinones A, Motu'apuaka M, Ensley M, Kansagara D, Brickell T, Grant I, Lange R, Kennedy J, Ivins B, Marshall K, Prokhorenko O, French L, Brickell T, Lange R, Bhagwat A, French L, Weber E, Nemeth D, Songy C, Gremillion A, Lange R, Brubacher J, Shewchuk J, Heran M, Jarrett M, Rauscher A, Iverson G, Woods S, Ukueberuwa D, Medaglia J, Hillary F, Meyer J, Vargas G, Rabinowitz A, Barwick F, Arnett P, Levan A, Gale S, Atkinson J, Boettcher A, Hill B, Rohling M, Stolberg P, Hart J, Allen D, Mayfield J, Ellis M, Marion SD, Houshyarnejad A, Grant I, Akarakian R, Kernan C, Babikian T, Asarnow R, Bens M, Fisher M, Garrett C, Vinogradov S, Walker K, Torstrick A, Uderman J, Wellington R, Zhao L, Fromm N, Dahdah M, Salisbury D, Monden K, Lande E, Wanlass R, Fong G, Smith K, Miele A, Novakovic-Agopian T, Chen A, Rome S, Rossi A, Abrams G, Murphy M, Binder D, Muir J, Carlin G, Loya F, Rabinovitz B, Bruhns M, Adler M, Schleicher-Dilks S, Messerly J, Babika C, Ukpabi C, Golden C, Schleicher-Dilks S, Coad S, Messerly J, Schaffer S, Babika C, Golden C, Cowad S, Paisley S, Fontanetta R, Messerly J, Golden C, Holder C, Kloezeman K, Henry B, Burns W, Patt V, Minassian A, Perry W, Cooper L, Allen D, Vogel S, Woolery H, Ciobanu C, Simone A, Bedard A, Olivier T, O'Neill S, Rajendran K, Halperin J, Rudd-Barnard A, Steenari M, Murry J, Le M, Becker T, Mucci G, Zupanc M, Shapiro E, Santos O, Cadavid N, Giese E, Londono N, Osmon D, Zamzow J, Culnan E, D'Argenio D, Mosti C, Spiers M, Schleicher-Dilks S, Kloss J, Curiel A, Miller K, Olmstead R, Gottuso A, Saucier C, Miller J, Dye R, Small G, Kent A, Andrews P, Puente N, Terry D, Faraco C, Brown C, Patel A, Siegel J, Miller L, Lee B, Joan M, Thaler N, Fontanetta R, Carla F, Allen D, Nguyen T, Glass L, Coles C, Julie K, May P, Sowell E, Jones K, Riley E, Demsky Y, Mattson S, Allart A, Freer B, Tiersky L, Sunderaraman P, Sylvester P, Ang J, Schultheis M, Newton S, Holland A, Burns K, Bunting J, Taylor J, Muetze H, Coe M, Harrison D, Putnam M, Tiersky L, Freer B, Holland A, Newton S, Sakamoto M, Bunting J, Taylor J, Coe M, Harrison D, Musso M, Hill B, Barker A, Pella R, Gouvier W, Davis J, Woods S, Wall J, Etherton J, Brand T, Hummer B, O'Shea C, Segovia J, Thomlinson S, Schulze E, Roskos P, Gfeller J, Loftis J, Fogel T, Barrera K, Sherzai A, Chappell A, Harrison A, Armstrong I, Flaro L, Pedersen H, Shultz LS, Roper B, Huckans M, Basso M, Silk-Eglit G, Stenclik J, Miele A, Lynch J, McCaffrey R, Silk-Eglit G, Stenclik J, Miele A, Lynch J, Musso M, McCaffrey R, Martin P, VonDran E, Baade L, Heinrichs R, Schroeder R, Hunter B, Calloway J, Rolin S, Akeson S, Westervelt H, Mohammed S, An K, Jeffay E, Zakzanis K, Lynch A, Drasnin D, Ikanga J, Graham O, Reid M, Cooper D, Long J, Lange R, Kennedy J, Hopewell C, Lukaszewska B, Pachalska M, Bidzan M, Lipowska M, McCutcheon L, Kaup A, Park J, Morgan E, Kenton J, Norman M, Martin P, Netson K, Woods S, Smith M, Paulsen J, Hahn-Ketter A, Paxton J, Fink J, Kelley K, Lee R, Pliskin N, Segala L, Vasilev G, Bozgunov K, Naslednikova R, Raynov I, Gonzalez R, Vassileva J, Bonilla X, Fedio A, Johnson K, Sexton J, Blackstone K, Weber E, Moore D, Grant I, Woods S, Pimental P, Welch M, Ring M, Stranks E, Crowe S, Jaehnert S, Ellis C, Prince C, Wheaton V, Schwartz D, Loftis J, Fuller B, Hoffman W, Huckans M, Turecka S, McKeever J, Morse C, Schultheis M, Dinishak D, Dasher N, Vik P, Hachey D, Bowman B, Van Ness E, Williams C, Zamzow J, Sunderaraman P, Kloss J, Spiers M, Swirsky-Sacchetti T, Alhassoon O, Taylor M, Sorg S, Schweinsburg B, Stricker N, Kimmel C, Grant I, Alhassoon O, Taylor M, Sorg S, Schweinsburg B, Stephan R, Stricker N, Grant I, Hertza J, Tyson K, Northington S, Loughan A, Perna R, Davis A, Collier M, Schroeder R, Buddin W, Schroeder R, Moore C, Andrew W, Ghelani A, Kim J, Curri M, Patel S, Denney D, Taylor S, Huberman S, Greenberg B, Lacritz L, Brown D, Hughes S, Greenberg B, Lacritz L, Vargas V, Upshaw N, Whigham K, Peery S, Casto B, Barker L, Otero T, La D, Nunan-Saah J, Phoong M, Gill S, Melville T, Harley A, Gomez R, Adler M, Tsou J, Schleicher-Dilks S, Golden C, Tsou J, Schleicher-Dilks S, Adler M, Golden C, Cowad S, Link J, Barker T, Gulliver K, Golden C, Young K, Moses J, Lum J, Vik P, Legarreta M, Van Ness E, Williams C, Dasher N, Williams C, Vik P, Dasher N, Van Ness E, Bowman B, Nakhutina L, Margolis S, Baek R, Gonzalez J, Hill F, England H, Horne-Moyer L, Stringer A, DeFilippis N, Lyon A, Giovannetti T, Fanning M, Heverly-Fitt S, Stambrook E, Price C, Selnes O, Floyd T, Vogt E, Thiruselvam I, Quasney E, Hoelzle J, Grant N, Moses J, Matevosyan A, Delano-Wood L, Alhassoon O, Hanson K, Lanni E, Luc N, Kim R, Schiehser D, Benners M, Downing K, Rowden A, Miller D, Maricle D, Kaminetskaya M, Moses J, Tai C, Kaminetskaya M, Melville T, Poole J, Scott R, Hays F, Walsh B, Mihailescu C, Douangratdy M, Scott B, Draffkorn C, Andrews P, Schmitt A, Waksmunski C, Brady K, Andrews A, Golden C, Olivier T, Espinoza K, Sterk V, Spengler K, Golden C, Olivier T, Spengler K, Sterk V, Espinoza K, Golden C, Gross J, DeFilippis N, Neiman-Kimel J, Romers C, Isaacs C, Soper H, Sordahl J, Tai C, Moses J, D'Orio V, Glukhovsky L, Beier M, Shuman M, Spat J, Foley F, Guatney L, Bott N, Moses J, Miranda C, Renteria MA, Rosario A, Sheynin J, Fuentes A, Byrd D, Mindt MR, Batchelor E, Meyers J, Patt V, Thomas M, Minassian A, Geyer M, Brown G, Perry W, Smith C, Kiefel J, Rooney A, Gouaux B, Ellis R, Grant I, Moore D, Graefe A, Wyman-Chick K, Daniel M, Beene K, Jaehnert S, Choi A, Moses J, Iudicello J, Henry B, Minassian A, Perry W, Marquine M, Morgan E, Letendre S, Ellis R, Woods S, Grant I, Heaton R, Constantine K, Fine J, Palewjala M, Macher R, Guatney L, Earleywine M, Draffkorn C, Scott B, Andrews P, Schmitt A, Dudley M, Silk-Eglit G, Stenclik J, Miele A, Lynch J, McCaffrey R, Scharaga E, Gomes W, McGinley J, Miles-Mason E, Colvin M, Carrion L, Romers C, Soper H, Zec R, Kohlrus S, Fritz S, Robbs R, Ala T, Zec R, Fritz S, Kohlrus S, Robbs R, Ala T, Edwards M, Hall J, O'Bryant S, Miller J, Dye R, Miller K, Baerresen K, Small G, Moskowitz J, Puente A, Ahmed F, Faraco C, Brown C, Evans S, Chu K, Miller L, Young-Bernier M, Tanguay A, Tremblay F, Davidson P, Duda B, Puente A, Terry D, Kent A, Patel A, Miller L, Junod A, Marion SD, Harrington M, Fonteh A, Gurnani A, John S, Gavett B, Diaz-Santos M, Mauro S, Beaute J, Cronin-Golomb A, Fazeli P, Gouaux B, Rosario D, Heaton R, Moore D, Puente A, Lindbergh C, Chu K, Evans S, Terry D, Duda B, Mackillop J, Miller S, Greco S, Klimik L, Cohen J, Robbins J, Lashley L, Schleicher-Dilks S, Golden C, Kunkes I, Culotta V, Kunkes I, Griffits K, Loughan A, Perna R, Hertza J, Cohen M, Northington S, Tyson K, Musielak K, Fine J, Kaczorowski J, Doty N, Braaten E, Shah S, Nemanim N, Singer E, Hinkin C, Levine A, Gold A, Evankovich K, Lotze T, Yoshida H, O'Bryan S, Roberg B, Glusman M, Ness A, Thelen J, Wilson L, Feaster T, Bruce J, Lobue C, Brown D, Hughes S, Greenberg B, Lacritz L, Bristow-Murray B, Andrews A, Bermudez C, Golden C, Moore R, Pulver A, Patterson T, Bowie C, Harvey P, Jeste D, Mausbach B, Wingo J, Fink J, Lee R, Pliskin N, Legenkaya A, Henry B, Minassian A, Perry W, McKeever J, Morse C, Thomas F, Schultheis M, Ruocco A, Daros A, Gill S, Grimm D, Saini G, Relova R, Hoblyn J, Lee T, Stasio C, Mahncke H, Drag L, Grimm D, Gill S, Saini G, Relova R, Hoblyn J, Lee T, Stasio C, Mahncke H, Drag L, Verbiest R, Ringdahl E, Thaler N, Sutton G, Vogel S, Reyes A, Ringdahl E, Vogel S, Freeman A, Call E, Allen D, March E, Salzberg M, Vogel S, Ringdahl E, Freeman A, Dadis F, Allen D, Sisk S, Ringdahl E, Vogel S, Freeman A, Allen D, DiGangi J, Silva L, Pliskin N, Thieme B, Daniel M, Jaehnert S, Noggle C, Thompson J, Kecala N, Lane E, Kane C, Noggle C, Thompson J, Lane E, Kecala N, Kane C, Palmer G, Happe M, Paxson J, Jurek B, Graca J, Olson S, Melville T, Harley A, La D, Phoong M, Gill S, Jocson VA, Nunan-Saah J, Keller J, Gomez R, Melville T, Kaminetskaya M, Poole J, Vernon A, Van Vleet T, DeGutis J, Chen A, Marini C, Dabit S, Gallegos J, Zomet A, Merzenich M, Thaler N, Linck J, Heyanka D, Pastorek N, Miller B, Romesser J, Sim A, Allen D, Zimmer A, Marcinak J, Hibyan S, Webbe F, Rainwater B, Francis J, Baum L, Sautter S, Donders J, Hui E, Barnes K, Walls G, Erikson S, Bailie J, Schwab K, Ivins B, Boyd C, Neff J, Cole W, Lewis S, Bailie J, Schwab K, Ivins B, Boyd C, Neff J, Cole W, Lewis S, Ramirez C, Oganes M, Gold S, Tanner S, Pina D, Merritt V, Arnett P, Heyanka D, Linck J, Thaler N, Pastorek N, Miller B, Romesser J, Sim A, Parks A, Roskos P, Gfeller J, Clark A, Isham K, Carter J, McLeod J, Romero R, Dahdah M, Barisa M, Schmidt K, Barnes S, Dubiel R, Dunklin C, Harper C, Callender L, Wilson A, Diaz-Arrastia R, Shafi S, Jacquin K, Bolshin L, Jacquin K, Romers C, Gutierrez E, Messerly J, Tsou J, Adler M, Golden C, Harmell A, Mausbach B, Moore R, Depp C, Jeste D, Palmer B, Hoadley R, Hill B, Rohling M, Mahdavi S, Fine J, daCruz K, Dinishak D, Richardson G, Vertinski M, Allen D, Mayfield J, Margolis S, Miele A, Rabinovitz B, Schaffer S, Kline J, Boettcher A, Hill B, Hoadley R, Rohling M, Eichstaedt K, Vale F, Benbadis S, Bozorg A, Rodgers-Neame N, Rinehardt E, Mattingly M, Schoenberg M, Fares R, Fares R, Carrasco R, Grups J, Evans B, Simco E, Mittenberg W, Carrasco R, Grups J, Evans B, Simco E, Mittenberg W, Rach A, Baughman B, Young C, Bene E, Irwin C, Li Y, Poulin R, Jerram M, Susmaras T, Gansler D, Ashendorf L, Miarmi L, Fazio R, Cantor J, Fernandez A, Godoy-Garcete G, Marchetti P, Harrison A, Armstrong I, Harrison L, Iverson G, Brinckman D, Ayaz H, Schultheis M, Heinly M, Vitelli K, Russler K, Sanchez I, Jones W, Loe S, Raines T, Hart J, Bene E, Li Y, Irwin C, Baughman B, Rach A, Bravo J, Schilling B, Weiss L, Lange R, Shewchuk J, Heran M, Rauscher A, Jarrett M, Brubacher J, Iverson G, Zink D, Barney S, Gilbert G, Allen D, Martin P, Schroeder R, Klas P, Jeffay E, Zakzanis K, Iverson G, Lanting S, Saffer B, Koehle M, Palmer B, Barrio C, Vergara R, Muniz M, Pinto L, Jeste D, Stenclik J, Lynch J, McCaffrey R, Shultz LS, Pedersen H, Roper B, Crouse E, Crucian G, Dezhkam N, Mulligan K, Singer R, Psihogios A, Davis A, Stephens B, Love C, Mulligan K, Webbe F, West S, McCue R, Goldin Y, Cicerone K, Ruchinskas R, Seidl JT, Massman P, Tam J, Schmitter-Edgecombe M, Baerresen K, Hanson E, Miller K, Miller J, Yeh D, Kim J, Ercoli L, Siddarth P, Small G, Noback M, Noback M, Baldock D, Mahmoud S, Munic-Miller D, Bonner-Jackson A, Banks S, Rabin L, Emerson J, Smith C, Roberts R, Hass S, Duhig A, Pankratz V, Petersen R, Leibson C, Harley A, Melville T, Phoong M, Gill S, Nunan-Saah J, La D, Gomez R, Lindbergh C, Puente A, Gray J, Chu K, Evans S, Sweet L, MacKillop J, Miller L, McAlister C, Schmitter-Edgecombe M, Baldassarre M, Kamm J, Wolff D, Dombrowski C, Bullard S, Edwards M, Hall J, Parsons T, O'Bryant S, Lawson R, Papadakis A, Higginson C, Barnett J, Wills M, Strang J, Dominska A, Wallace G, Kenworthy L, Bott N, Kletter H, Carrion V, Ward C, Getz G, Peer J, Baum C, Edner B, Mannarino A, Casnar C, Janke K, van der Fluit F, Natalie B, Haberman D, Solomon M, Hunter S, Klein-Tasman B, Starza-Smith A, Talbot E, Hart A, Hall M, Baker J, Kral M, Lally M, Zisk A, Lo T, Ross P, Cuevas M, Patel S, Lebby P, Mouanoutoua A, Harrison J, Pollock M, Mathiowetz C, Romero R, Boys C, Vekaria P, Vasserman M, MacAllister W, Stevens S, Van Hecke A, Carson A, Karst J, Schohl K, Dolan B, McKindles R, Remel R, Reveles A, Fritz N, McDonald G, Wasisco J, Kahne J, Hertza J, Tyson K, Northington S, Loughan A, Perna R, Newman A, Garmoe W, Clark J, Loughan A, Perna R, Hertza J, Cohen M, Northington S, Tyson K, Whithers K, Puente A, Dedmon A, Capps J, Lindsey H, Francis M, Weigand L, Steed A, Puente A, Edmed S, Sullivan K, Puente A, Lindsey H, Dedmon A, Capps J, Whithers K, Weigand L, Steed A, Kark S, Lafleche G, Brown T, Bogdanova Y, Strongin E, Spickler C, Drasnin D, Strongin C, Poreh A, Houshyarnejad A, Ellis M, Babikian T, Kernan C, Asarnow R, Didehbani N, Cullum M, Loneman L, Mansinghani S, Hart J, Fischer J. POSTER SESSIONS SCHEDULE. Arch Clin Neuropsychol 2013. [DOI: 10.1093/arclin/act054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
172
|
Gandia J, Njoroge R, Johnson K, Bryan A, Berry A, Heath A. Utilizing a Electronic Medication Reconciliation Form to Improve Clinical Outcomes of Chronic Heart Failure Patients. Heart Lung 2013. [DOI: 10.1016/j.hrtlng.2013.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
173
|
Johnson K, Goodson J, Porter G, Tisch J. Compliance with Therapy as Recommended by the New Zealand and Australasian ACS Guideline in Tauranga Hospital. Heart Lung Circ 2013. [DOI: 10.1016/j.hlc.2013.04.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
174
|
Bowler KE, Worsley MA, Broad L, Sher E, Benschop R, Johnson K, Yates JM, Robinson PP, Boissonade FM. Evidence for anti-inflammatory and putative analgesic effects of a monoclonal antibody to calcitonin gene-related peptide. Neuroscience 2012; 228:271-82. [PMID: 23098803 DOI: 10.1016/j.neuroscience.2012.10.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Revised: 09/26/2012] [Accepted: 10/13/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND Calcitonin gene-related peptide (CGRP) is a powerful pro-inflammatory mediator thought to play a significant role in the development of inflammation and pain. We investigated the role of CGRP in trigeminal inflammatory pain by determining the ability of a monoclonal antibody to CGRP to modify central Fos expression in response to stimulation of the inflamed ferret tooth pulp. We also assessed the effect of the antibody on pulpal inflammation. METHODS Ten adult ferrets were prepared under anaesthesia to allow stimulation of the upper and lower left canine pulps, recording from the digastric muscle and intravenous injections at subsequent experiments. In all animals, pulpal inflammation was induced by introducing human caries into a deep buccal cavity. Four days later animals were treated intravenously with either CGRP antibody (n=5) or vehicle (n=5). After a further 2 days animals were re-anaesthetised and the tooth pulps stimulated at 10 times jaw-opening reflex threshold. Brainstems and tooth pulps were processed immunohistochemically for Fos and the common leucocyte marker CD45, respectively. RESULTS Fos was expressed in ipsilateral trigeminal subnuclei caudalis (Vc) and oralis (Vo). Significantly fewer Fos-positive nuclei were present within Vc of CGRP antibody-treated animals (p=0.003 vs vehicle-treated). Mean percentage area of staining for CD45 was significantly less in antibody-treated animals (p=0.04 vs vehicle-treated). CONCLUSIONS This is the first direct evidence that sequestration of CGRP has anti-inflammatory and putative analgesic effects. Previous studies using this Fos model have demonstrated that it is able to predict clinical analgesic efficacy. Thus these data indicate that this antibody may have analgesic effects in dental pain and other types of inflammatory-mediated transmission, and suggest that this is in part due to peripheral anti-inflammatory effects.
Collapse
Affiliation(s)
- K E Bowler
- Unit of Oral & Maxillofacial Medicine & Surgery, School of Clinical Dentistry, University of Sheffield, Claremont Crescent, Sheffield S10 2TA, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
175
|
Moon H, Natavio M, Moore K, Lou M, Besinque K, Johnson K, Opper N, Bender N, Frausto S, Segall-Gutierrez P. Factors influencing pharmacy students' likelihood of recommending oral emergency contraception. Contraception 2012. [DOI: 10.1016/j.contraception.2012.05.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
176
|
Kelley RT, Hannans A, Kreps GL, Johnson K. The Community Liaison Program: a health education pilot program to increase minority awareness of HIV and acceptance of HIV vaccine trials. Health Educ Res 2012; 27:746-754. [PMID: 22327809 PMCID: PMC3529630 DOI: 10.1093/her/cys013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2010] [Accepted: 01/17/2011] [Indexed: 05/31/2023]
Abstract
This paper describes a 16-month health education pilot program based on diffusion of innovation and social network theories. The program was implemented by volunteer community liaisons for the purposes of increasing awareness of and support for HIV vaccine research in minority populations. This theoretically driven pilot program allowed the liaisons to integrate delivery of the HIV vaccine research messages created for the program into their existing activities and routines. Through training in participatory engagement, volunteers were able to tailor and adapt an HIV prevention message for their communities. Process evaluation data showed that the acceptance of participatory engagement and HIV vaccine message dissemination far exceeded expectations. The anticipated number of community members to receive the message was estimated at 500 with 10 volunteer liaisons or 50 per person. However, the actual number of people reached was 644, with only 7 volunteer liaisons, or an average of 92 persons per liaison, almost double the original number. Further research is recommended to analyze the specific behavioral changes that can come from the use of social networks in HIV vaccine research awareness within minority populations.
Collapse
Affiliation(s)
- R T Kelley
- Division of Community Advancement and Leadership Strategies, National Minority AIDS Council, Washington, DC 20009, USA.
| | | | | | | |
Collapse
|
177
|
Curtis A, Wood A, Johnson K, Walker J, Dornburg S, Osser-Burgess A, Markham E, Nack J. 6. The importance of daily weight measurements in heart failure patients: a performance improvement project. Heart Lung 2012. [DOI: 10.1016/j.hrtlng.2012.04.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
178
|
Cohen L, Chandwani K, Raghuram N, Haddad R, Perkins G, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Nagendra H. OA10.02. Yoga for women with breast cancer undergoing radiotherapy (XRT): a randomized clinical trial with an active stretching control group. Altern Ther Health Med 2012. [PMCID: PMC3373721 DOI: 10.1186/1472-6882-12-s1-o38] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
179
|
Wormsbecker A, Dang V, Jamieson F, Wilson S, Rawte P, Crowcroft NS, Johnson K, Deeks SL. Serogroup C Invasive Meningococcal Disease (IMD) In Ontario, Canada, 2000–2010: Vaccine Impact Assessment. Paediatr Child Health 2012. [DOI: 10.1093/pch/17.suppl_a.27aa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
180
|
Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92:87-95. [PMID: 22588608 DOI: 10.1038/clpt.2011.371] [Citation(s) in RCA: 301] [Impact Index Per Article: 25.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The promise of "personalized medicine" guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision-support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health-care provider, identification of relevant genetic variations for implementation, assay reliability, point-of-care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point-of-care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.
Collapse
Affiliation(s)
- J M Pulley
- Department of Medical Administration, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
181
|
Boeve B, Daube J, DeJesus-Hernandez M, Parisi J, Dickson D, Josephs K, Baker M, Kuntz K, Johnson K, Knopman D, Ivnik R, Petersen R, Rademakers R. A Kindred with Familial Frontotemporal Dementia and/or Amyotrophic Lateral Sclerosis Associated with the GGGGCC Repeat Expansion in C9ORF72 (P05.058). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
182
|
Marshall G, Lorius N, Gidicsin C, Maye J, Becker JA, Amariglio R, Rentz D, Sperling R, Johnson K. Instrumental Activities of Daily Living Impairment Is Associated with Temporal and Parietal Hypometabolism in Mild Cognitive Impairment (P04.214). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p04.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
183
|
Natavio M, Moore K, Segall-Gutierrez P, Moon H, Besinque K, Opper N, Bender N, Taylor D, Johnson K. Emergency contraception skills workshop for first-year pharmacy students. Contraception 2012. [DOI: 10.1016/j.contraception.2011.11.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
184
|
Komber H, Senkovskyy V, Tkachov R, Johnson K, Kiriy A, Huck WTS, Sommer M. Ring Walking versus Trapping of Nickel(0) during Kumada Catalyst Transfer Polycondensation Using Externally Initiated Electron-Accepting Thiophene–Benzothiadiazole–Thiophene Precursors. Macromolecules 2011. [DOI: 10.1021/ma2018827] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- H. Komber
- Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Strasse 6, 01069 Dresden, Germany
| | - V. Senkovskyy
- Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Strasse 6, 01069 Dresden, Germany
| | - R. Tkachov
- Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Strasse 6, 01069 Dresden, Germany
| | - K. Johnson
- Cavendish Laboratory, J J Thomson Avenue, Cambridge CB3 0HE, U.K
| | - A. Kiriy
- Leibniz-Institut für Polymerforschung Dresden e.V., Hohe Strasse 6, 01069 Dresden, Germany
| | - W. T. S. Huck
- Melville Laboratory for Polymer Synthesis, Lensfield Road, Cambridge CB2 1EW, U.K
- Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, Netherlands
| | - M. Sommer
- Melville Laboratory for Polymer Synthesis, Lensfield Road, Cambridge CB2 1EW, U.K
| |
Collapse
|
185
|
Gore C, Custovic A, Tannock GW, Munro K, Kerry G, Johnson K, Peterson C, Morris J, Chaloner C, Murray CS, Woodcock A. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy 2011; 42:112-22. [PMID: 22092692 DOI: 10.1111/j.1365-2222.2011.03885.x] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Revised: 07/25/2011] [Accepted: 08/12/2011] [Indexed: 11/28/2022]
Abstract
BACKGROUND Allergic disease has been associated with altered intestinal microbiota. Therefore, probiotics have been suggested as a potential treatment for eczema. OBJECTIVE We investigated whether dietary supplementation of infants with eczema at age 3-6 months with Lactobacillus paracasei CNCM I-2116 or Bifidobacterium lactis CNCM I-3446 had a treatment effect or altered allergic disease progression. METHODS Primary outcome included eczema severity (SCORing Atopic Dermatitis, SCORAD) 3 months post-randomization. Secondary: SCORAD (other visits); infant dermatitis quality of life (IDQoL); gastrointestinal permeability; urinary eosinophilic protein X; allergen-sensitization; allergic symptoms (age 12, 18, 36 months). A total of 208 infants aged 3-6 months with physician-diagnosed eczema were recruited; 137/208 (SCORAD ≥ 10, consuming ≥ 200 mL standard formula/day) were randomized to daily supplements containing L. paracasei or B. lactis or placebo for a 3-month period, while receiving extensively hydrolysed whey-formula (dairy-free diet). There were two open observational groups, one group exclusively breastfed (n = 22) and the other, standard formula-fed (n = 49). TRIAL NUMBER ISRCTN41490500. RESULTS Eczema severity decreased significantly over time in all groups. No significant difference was observed between randomized groups after 12-week treatment-period (SCORAD-score pre-/post-intervention: B. lactis 25.9 [95% CI: 22.8-29.2] to 12.8 [9.4-16.6]; L. paracasei 25.4 [22.1-29] to 12.5 [9.2-16.4]; placebo 26.9 [23.4-30.6] to 11.8 [9.6-14.3]; P = 0.7). Results were similar when analysis was controlled for allergen-sensitization, or when only sensitized infants were analysed. No differences were found for secondary outcomes. No difference was observed in SCORAD-score between randomized and observational groups. CONCLUSION AND CLINICAL RELEVANCE We found no benefit from supplementation with B. lactis or L. paracasei in the treatment of eczema, when given as an adjunct to basic topical treatment, and no effect on the progression of allergic disease from age 1 to 3 years.
Collapse
Affiliation(s)
- C Gore
- School of Translational Medicine, University of Manchester, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
186
|
Liebich T, McCormick SD, Kircheis D, Johnson K, Regal R, Hrabik T. Water chemistry and its effects on the physiology and survival of Atlantic salmon Salmo salar smolts. J Fish Biol 2011; 79:502-519. [PMID: 21781105 DOI: 10.1111/j.1095-8649.2011.03046.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The physiological effects of episodic pH fluctuations on Atlantic salmon Salmo salar smolts in eastern Maine, U.S.A., were investigated. During this study, S. salar smolts were exposed to ambient stream-water chemistry conditions at nine sites in four catchments for 3 and 6 day intervals during the spring S. salar smolt migration period. Plasma chloride, plasma glucose, gill aluminium and gill Na(+)- and K(+)-ATPase levels in S. salar smolts were assessed in relation to ambient stream-water chemistry during this migration period. Changes in both plasma chloride and plasma glucose levels of S. salar smolts were strongly correlated with stream pH, and S. salar smolt mortality occurred in one study site with ambient stream pH between 5·6 and 5·8 during the study period. The findings from this study suggest that physiological effects on S. salar smolts are strongly correlated with stream pH and that in rivers and streams with low dissolved organic carbon (DOC) concentrations the threshold for physiological effects and mortality probably occurs at a higher pH and shorter exposure period than in rivers with higher DOC. Additionally, whenever an acidification event in which pH drops below 5·9 coincides with S. salar smolt migration in eastern Maine rivers, there is potential for a significant reduction in plasma ions of S. salar smolts.
Collapse
Affiliation(s)
- T Liebich
- USFWS, Izembek National Wildlife Refuge, 1 Izembek Street, Cold Bay, AK 99571, USA.
| | | | | | | | | | | |
Collapse
|
187
|
Raedler H, Vieyra MB, Leisman S, Lakhani P, Kwan W, Yang M, Johnson K, Faas SJ, Tamburini P, Heeger PS. Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant 2011; 11:1397-406. [PMID: 21668627 PMCID: PMC3128644 DOI: 10.1111/j.1600-6143.2011.03561.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
While activation of serum complement mediates antibody-initiated vascular allograft injury, increasing evidence indicates that complement also functions as a modulator of alloreactive T cells. We tested whether blockade of complement activation at the C5 convertase step affects T cell-mediated cardiac allograft rejection in mice. The anti-C5 mAb BB5.1, which prevents the formation of C5a and C5b, synergized with subtherapeutic doses of CTLA4Ig to significantly prolong the survival of C57BL/6 heart grafts that were transplanted into naive BALB/c recipients. Anti-C5 mAb treatment limited the induction of donor-specific IFNγ-producing T cell alloimmunity without inducing Th2 or Th17 immunity in vivo and inhibited primed T cells from responding to donor antigens in secondary mixed lymphocyte responses. Additional administration of anti-C5 mAb to the donor prior to graft recovery further prolonged graft survival and concomitantly reduced both the in vivo trafficking of primed T cells into the transplanted allograft and decreased expression of T cell chemoattractant chemokines within the graft. Together these results support the novel concept that C5 blockade can inhibit T cell-mediated allograft rejection through multiple mechanisms, and suggest that C5 blockade may constitute a viable strategy to prevent and/or treat T cell-mediated allograft rejection in humans.
Collapse
Affiliation(s)
- H Raedler
- Division of Nephrology, Mount Sinai School of Medicine, New York, NY, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
188
|
Mulder T, Johnson K, Lifflander A, Schillinger J, Rogers M, Blank S. P3-S1.10 Using electronic medical record data to guide expedited partner therapy implementation in an urban STD clinic system, 2009. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050108.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
189
|
Zhou ZY, Wu J, Baker J, Curtis R, Forsberg A, Huszti H, Koerper M, Lou M, Miller R, Parish K, Riske B, Shapiro A, Ullman M, Johnson K. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011; 17:729-36. [PMID: 21689212 DOI: 10.1111/j.1365-2516.2011.02595.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
To describe the study design, procedures and baseline characteristics of the Haemophilia Utilization Group Study - Part Va (HUGS Va), a US multi-center observational study evaluating the cost of care and burden of illness in persons with factor VIII deficiency. Patients with factor VIII level ≤ 30%, age 2-64 years, receiving treatment at one of six federally supported haemophilia treatment centres (HTCs) were enrolled in the study. Participants completed an initial interview including questions on socio-demographical characteristics, health insurance status, co-morbidities, access to care, haemophilia treatment regimen, factor utilization, self-reported joint pain and motion limitation and health-related quality of life. A periodic follow-up survey collected data regarding time lost from usual activities, disability days, health care utilization and outcomes of care. HTC clinicians documented participants' baseline clinical characteristics and pharmacy dispensing records for 2 years. Between July 2005 and July 2007, 329 participants were enrolled. Average age was 9.7 years for children and 33.5 years for adults; two-thirds had severe haemophilia. The distributions of age, marital status, education level and barriers to haemophilia care were relatively consistent across haemophilic severity categories. Differences were found in participants' employment status, insurance status and income. Overall, children with haemophilia had quality of life scores comparable to healthy counterparts. Adults had significantly lower physical functioning than the general US population. As one of the largest economic studies of haemophilia care, HUGS Va will provide detailed information regarding the burden of illness and health care utilization in the US haemophilia A population.
Collapse
Affiliation(s)
- Z-Y Zhou
- University of Southern California, Los Angeles, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
190
|
Goss PE, Ingle JN, Ales-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba504] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA504 Background: Limited efficacy and serious toxicities have limited uptake of tamoxifen or raloxifene as preventatives of breast cancer. Aromatase inhibitors (AIs) prevent contralateral breast cancers more than tamoxifen in adjuvant trials and have fewer serious side effects. This is the first report of an AI used in primary prevention. Methods: NCIC CTG MAP.3 is a randomized trial designed to detect a 65% reduction in annual incidence of invasive breast cancer (IBC) on exemestane (E) versus placebo (P). Eligible postmenopausal women had ≥ one of the following risk factors: Gail score >1.66%, prior ADH, ALH, LCIS or DCIS with mastectomy, age over 60. Health-related and menopause-specific quality of life (QOL) were assessed by SF-36 and MENQOL questionnaires. Results: From 2004-2010, 4,560 women were randomized: age 62.5 yrs (37-90); Gail Score 2.3 % (0.6-21); BMI 28.0 kg/m2 (15.9-65.4). Risk factors included: age >60 yrs (49%); Gail score >1.66 (40%); and prior ADH, ALH, LCIS or DCIS with mastectomy (11%). At median follow-up of 35 months there were 11 IBCs on E and 32 on P (annual incidence 0.19% vs 0.55%; HR= 0.35, 95% CI 0.18-0.70, p = 0.002); ductal (10E/27P), lobular (1E/5P). Most tumors were ER positive (7E/27P); Her2/neu negative (10E/26P); TNM stage T1 (8E/28P), N0 (7E/22P), M0 (11E/30P). E was superior in all subgroups: by Gail score, age, BMI, prior LCIS and DCIS. The annual incidence rate of IBC or DCIS was 0.35% E and 0.77% P (HR=0.47;95% CI 0.27-0.79; p = 0.004) based on 64 IBCs or DCISs (20E/44P). Clinical bone fractures, osteoporosis, hypercholesterolemia or cardiovascular events were equal in both arms. No clinically meaningful differences in QOL were detected. Conclusions: Exemestane significantly reduced invasive and pre-invasive breast cancers in postmenopausal women at increased risk for breast cancer with no serious toxicities. Exemestane should be considered a new option for primary prevention of breast cancer. Supported by the Canadian Cancer Society; Pfizer Inc. PEG supported in part by Avon Foundation.
Collapse
Affiliation(s)
- P. E. Goss
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. N. Ingle
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Ales-Martinez
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - A. Cheung
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - R. T. Chlebowski
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Wactawski-Wende
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - A. McTiernan
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Robbins
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - K. Johnson
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - L. Martin
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - E. Winquist
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - G. Sarto
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. E. Garber
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - C. J. Fabian
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - P. Pujol
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - E. Maunsell
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - P. Farmer
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - K. A. Gelmon
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - D. Tu
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - H. Richardson
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| |
Collapse
|
191
|
Cohen L, Chandwani K, Raghuram NV, Haddad R, Perkins GH, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Nagendra HR. Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
192
|
Goss PE, Ingle JN, Ales-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
193
|
Chang W, Frydrychowicz A, Kecskemeti S, Landgraf B, Johnson K, Wu Y, Wieben O, Mistretta C, Turski P. The effect of spatial resolution on wall shear stress measurements acquired using radial phase contrast magnetic resonance angiography in the middle cerebral arteries of healthy volunteers. Preliminary results. Neuroradiol J 2011; 24:115-20. [PMID: 24059578 DOI: 10.1177/197140091102400116] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2010] [Accepted: 01/03/2011] [Indexed: 11/15/2022] Open
Abstract
We have recently implemented radial phase-contrast techniques that allow high resolution angiograms with velocity information to be acquired within clinically-useful imaging times. 10 healthy volunteers were scanned using PC-VIPR and PC-SOS, two high resolution phase-contrast techniques at spatial resolutions of 0.67×0.67×0.67 mm(3) and 0.4×0.4×1 mm(3) respectively. The velocity measurements from the two acquisitions were imported into a custom Matlab runtime environment that automatically calculated WSS values using Green's Theorem and B-spline interpolation. Time average axial WSS was 1.069 N/m(2) (95% confidence interval: 0.8628< x < 1.276) in the left and right middle cerebral arteries of the 10 healthy volunteers (n=20) when scanned by PC-VIPR, and 1.670 N/m(2) when scanned by PC-SOS (95% confidence interval: 1.395 < x < 1.946). This difference in means was statistically significant (p < 0.002). Previous investigators have found that higher spatial resolution results in higher WSS measurements because smaller voxel size results in fewer partial volume effects. This was true in our study as well. In this study, we found that PC-SOS has significantly higher spatial resolution than PC-VIPR and this followed in the WSS measurements. Higher in-plane spatial resolution allows WSS calculations to be performed more accurately because of increased precision near the vessel boundary.
Collapse
Affiliation(s)
- W Chang
- Department of Medical Physics; Department of Radiology; University of Wisconsin School of Medicine and Public Health; Madison, Wisconsin, USA -
| | | | | | | | | | | | | | | | | |
Collapse
|
194
|
Abstract
Abstract
Dairy heifers, particularly when <3 months, are at high risk for mortality and morbidity. Accurate data are lacking because of poor recording on farm, difficulties over disease diagnosis and potential bias of farm selection. Mortality during rearing varied from 6 to 14% between studies. The range from 0 to 30% on individual farms suggested that deaths are preventable with good husbandry. Contagious disease was the major cause of mortality at <6 months, with trauma, accidents and infertility more important in older animals. Bovine respiratory disease (BRD) and diarrhoea were the most common diseases. Both are endemic, low-mortality and high-morbidity conditions. The prevalence of diarrhoea was 19-35%, with higher incidences during disease outbreaks. Cryptosporidium parvum and rotavirus were the dominant pathogens. The causative pathogens for BRD were harder to identify, with large differences between levels of farmer- and veterinarian-diagnosed disease and higher incidences in North America (around 16%) than Europe (around 3%). Analysis of the risk factors for disease and mortality highlighted that closed herds, good hygiene and availability of roughage were consistently associated with improved outcomes. Some common practices were challenged by the results of large, prospective studies. Calf diarrhoea was only weakly associated with good passive transfer of immunity via colostrum, suggesting other control strategies are required. Morbidity with small group housing demonstrated no disadvantages compared with contiguous single pens, so this system should be encouraged to improve welfare. Routine use of antibiotics in calf diarrhoea was associated with negative outcomes, so is actively discouraged.
Collapse
|
195
|
Leung RS, Fairhurst J, Johnson K, Landes C, Moon L, Sprigg A, Offiah AC. Teleradiology: a modern approach to diagnosis, training, and research in child abuse? Clin Radiol 2011; 66:546-50. [PMID: 21310398 DOI: 10.1016/j.crad.2010.11.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2010] [Revised: 11/22/2010] [Accepted: 11/25/2010] [Indexed: 10/18/2022]
Affiliation(s)
- R S Leung
- Department of Radiology, Great Ormond Street Hospital for Children, London, UK
| | | | | | | | | | | | | |
Collapse
|
196
|
Johnson K, Keet C, Hamilton R, Wood R. Predictive Value of Peanut Component Specific IgE in a Clinical Population. J Allergy Clin Immunol 2011. [DOI: 10.1016/j.jaci.2010.12.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
197
|
Heckman-Stoddard BM, Grubbs CJ, Johnson K, Lubet RA. Abstract P1-08-04: Doses of Selective Estrogen Receptor Modulations (SERMS) Required for Prevention and Therapy of Chemically-Induced Mammary Cancers. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Selective Estrogen Receptor Modulators (SERMs) interfere with the activation of the estrogen receptor. SERMs have been shown to be effective for both treatment and prevention of breast cancer. Here we examine the ability of tamoxifen and arzoxifene, a more easily absorbed form of raloxifene, to prevent mammary tumors at a significantly lower dosage than those used for treatment. For prevention studies, female Sprague-Dawley rats (50 days of age) were injected with a single i.v. dose of MNU resulting in the development of multiple ER-positive mammary tumors beginning 7 weeks after carcinogen treatment. Rats were administered the preventive agent beginning five days after carcinogen administration. When the agents were tested at does varying between 0.15-3.3 ppm in the diet, both agents caused a dose dependent increase in preventive activity. The highest doses of tamoxifen (3.3 ppm) and arzoxifene (3.0 ppm) both decreased tumor multiplicity greater than 90%. Both of these doses are less than one-fifth the human equivalent dose (HED) based on standard FDA scaling factors. Both doses also resulted in substantial decreases in mammary gland development. These dosages were then used in a therapy setting to compare the efficacy. For these studies, MNU treated rats were allowed to develop their first palpable mammary tumor (70-150 mm2) before initiating treatment. Tumor growth or regression was followed by caliper measurements. Neither of the preventive doses of these SERMs exhibited therapeutic activity although substantially higher doses of tamoxifen (33 or 100 ppm) were relatively effective. These results are in contrast to our prior findings with other classes of agents (RXR agonists, EGFR inhibitors, and aromatase inhibitors) in which highly effective preventive doses were as effective as therapeutic doses in this model. These results demonstrate the unique dose differential regarding prevention and therapy with SERMs. Microarray analysis of tumors treated for 5 days with tamoxifen at doses of 3.3ppm or 100ppm reveals overlapping significant gene changes of similar magnitude in comparison to control treated tumors although there were significant gene changes seen at the therapeutic dose which were not observed at the lower dose. These studies raise two questions: 1) whether this class of agents might be used at significantly lower doses in a pure prevention setting as contrasted with a therapeutic setting where they were initially defined; 2) are there gene expression changes which might be used to help identify this differential dosing for prevention vs. therapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-08-04.
Collapse
Affiliation(s)
- BM Heckman-Stoddard
- National Cancer Institute, Bethesda, MD; University of Alabama at Birmingham
| | - CJ Grubbs
- National Cancer Institute, Bethesda, MD; University of Alabama at Birmingham
| | - K Johnson
- National Cancer Institute, Bethesda, MD; University of Alabama at Birmingham
| | - RA. Lubet
- National Cancer Institute, Bethesda, MD; University of Alabama at Birmingham
| |
Collapse
|
198
|
Barzana D, Johnson K, Clancy TV, Hope WW. Hernia recurrence through a composite mesh secondary to transfascial suture holes. Hernia 2010; 16:219-21. [PMID: 20835907 DOI: 10.1007/s10029-010-0728-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2010] [Accepted: 08/26/2010] [Indexed: 11/26/2022]
Abstract
Laparoscopic ventral hernia repair is an accepted method for incisional hernia repair. Although techniques vary, transfascial suturing of the mesh to the abdominal wall has been proposed as a viable way to fixate the mesh and reduce recurrence rates. We report a 54-year-old woman who had previously undergone a laparoscopic ventral hernia repair following a laparoscopic tubal ligation using a Composix mesh. The patient presented with a symptomatic hernia recurrence. The computed tomography scan showed a periumbilical hernia containing fat. The patient underwent diagnostic laparoscopy and lysis of adhesions. During the lysis of adhesions, a recurrence through the previously placed composite mesh was encountered where holes had been made by the previously placed transfascial sutures. The hernia was reduced, mesh was removed, and an ePTFE mesh was used to repair the hernia. The mechanism of recurrence appeared to be improperly placed transfascial sutures; overly large bites of mesh caused excessive tension and ultimately a hole in the mesh. Hernia recurrence due to mesh or transfascial suture failure is rarely reported and most often caused by inadequate fixation. Our case highlights the need for meticulous placement of transfascial sutures and demonstrates a mechanism of recurrence due to inadequate placement.
Collapse
Affiliation(s)
- D Barzana
- Department of Surgery, New Hanover Regional Medical Center, South East Area Health Education Center, Wilmington, NC 28401, USA
| | | | | | | |
Collapse
|
199
|
Escabi Y, San Miguel L, Judd T, Hertza J, Nicholson J, Schiff W, Bell C, Estes B, Millikin C, Shelton P, Marotta P, Wingler I, Barth J, Parmenter B, Andrews G, Riordan P, Lipinski D, Sawyer J, Brewer V, Kirk J, Green C, Kirkwood M, Brooks B, Fay T, Barlow K, Chelune G, Duff K, Wang A, Franchow E, Card S, Zamrini E, Foster N, Duff K, Chelune G, Wang A, Card S, Franchow E, Zamrini E, Foster N, Green D, Polikar R, Clark C, Kounios J, Malek-Ahmadi M, Kataria R, Belden C, Connor D, Pearson C, Jacobson S, Yaari R, Singh U, Sabbagh M, Manning K, Arnold S, Moelter S, Davatzikos C, Clark C, Moberg P, Singer R, Seelye A, Smith A, Schmitter-Edgecombe M, Viamonte S, Murman D, West S, Fonseca F, McCue R, Golden C, Cox D, Crowell T, Fazeli P, Vance D, Ross L, Ackerman M, Hill B, Tremont G, Davis J, Westervelt H, Alosco M, O'Connor K, Ahearn D, Pella R, Jain G, Noggle C, Sohi J, Jeetwani A, Thompson J, Barisa M, Sohi J, Noggle C, Jeetwani A, Jain S, Thompson J, Barisa M, Vanderslice-Barr J, Gillen R, Zimmerman E, Holdnack J, Creamer S, Rice J, Fitzgerald K, Elbin R, Patwardhan S, Covassin T, Kiewel N, Kontos A, Meyers C, Hakun J, Ravizza S, Berger K, Paltin I, Hertza J, Phillips F, Estes B, Schiff W, Bell C, Anderson J, Horton A, Reynolds C, Huckans M, Vandenbark A, Dougherty M, Loftis J, Langill M, Roberts R, Iverson G, Appel-Cresswell S, Stoessl A, Lazarus J, Olcese R, Juncos J, McCaskell D, Walsh K, Allen E, Shubeck L, Hamilton D, Novack G, Sherman S, Livingson R, Schmitt A, Stewart R, Doyle K, Smernoff E, West S, Galusha J, Hua S, Mattingly M, Rinehardt E, Benbadis S, Borzog A, Rogers-Neame N, Vale F, Frontera A, Schoenberg M, Rosenbaum K, Norman M, Woods S, Houshyarnejad A, Filoteo W, Corey-Bloom J, Pachet A, Larco C, Raymond M, Rinehardt E, Mattingly M, Golden C, Benbadis S, Borzog A, Rogers-Neame N, Vale F, Frontera A, Schoenberg M, Schmitt A, Stewart R, Livingston R, Doyle K, Copenheaver D, Smernoff E, Werry A, Claunch J, Galusha J, Uysal S, Mazzeffi M, Lin H, Reich D, August-Fedio A, Sexton J, Zand D, Keller J, Thomas T, Fedio P, Austin A, Millikin C, Baade L, Shelton P, Yamout K, Marotta J, Boatwright B, Kardel P, Heinrichs R, Blake T, Silverberg N, Anton H, Bradley E, Lockwood C, Hull A, Poole J, Demadura T, Storzbach D, Acosta M, Tun S, Hull A, Greenberg L, Lockwood C, Hutson L, Belsher B, Sullivan C, Poole J, La Point S, Harrison A, Packer R, Suhr J, Heilbronner R, Lange R, Iverson G, Brubacher J, Lange R, Waljas M, Iverson G, Hakulinen U, Dastidar P, Trammell B, Hartikainen K, Soimakallio S, Ohman J, Lee-Wilk T, Ryan P, Kurtz S, Dux M, Dischinger P, Auman K, Murdock K, Mazur-Mosiewicz A, Kane R, Lockwood C, Hull A, Poole J, MacGregor A, Watt D, Puente A, Marceaux J, Dilks L, Carroll A, Dean R, Ashworth B, Dilks S, Thrasher A, Carbonaro S, Blancett S, Ringdahl E, Finton M, Thaler N, Drane D, Umuhoza D, Barber B, Schoenberg M, Umuhoza D, Allen D, Roebuck-Spencer T, Vincent A, Schlegel R, Gilliland K, Lazarus T, Brown F, Katz L, Mucci G, Franchow E, Suchy Y, Kraybill M, Eastvold A, Funes C, Stern S, Morris M, Graham L, Parikh M, Hynan L, Buchbinder D, Grosch M, Weiner M, Cullum M, Hart J, Lavach J, Holcomb M, Allen R, Holcomb M, Renee A, Holland A, Chang R, Erdodi L, Hellings J, Catoe A, Lajiness-O'Neill R, Whiteside D, Smith A, Brown J, Hardin J, Rutledge J, Carmona J, Wang R, Harrison D, Horton A, Reynolds C, Horton A, Reynolds C, Jurado M, Monroy M, Eddinger K, Serrano M, Rosselli M, Chakravarti P, Riccio C, Banville F, Schretlen D, Wahlberg A, Vannorsdall T, Yoon H, Sung K, Simek A, Gordon B, Vaughn C, Kibby M, Barwick F, Arnett P, Rabinowitz A, Vargas G, Barwick F, Arnett P, Rabinowitz A, Vargas G, Davis J, Ramos C, Hynd G, Sherer C, Stone M, Wall J, Davis J, Bagley A, McHugh T, Axelrod B, Hanks R, Denning J, Gervais R, Dougherty M, Sellbom M, Wygant D, Klonoff P, Lange R, Iverson G, Carone D, O'Connor Pennuto T, Kluck A, Ball J, Pella R, Rice J, Hietpas-Wilson T, McCoy K, VanBuren K, Hilsabeck R, Shahani L, Noggle C, Jain G, Sohi J, Thomspon J, Barisa M, Golden C, Vincent A, Roebuck-Spencer T, Cooper D, Bowles A, Gilliland K, Womble M, Rohling M, Gervais R, Greiffenstein M, Harrison A, Jones K, Suhr J, Armstrong C, Mazur-Mosiewicz A, Holcomb M, Trammell B, Dean R, Puente A, Whigham K, Rodriguez M, West S, Golden C, Kelley E, Poole J, Larco C, May N, Nemeth D, Olivier T, Whittington L, Hamilton J, Steger A, McDonald K, Jeffay E, Gammada E, Zakzanis K, Ramanathan D, Wardecker B, Slocomb J, Hillary F, Rohling M, Demakis G, Larrabee G, Binder L, Ploetz D, Schatz P, Smith A, Stolberg P, Thayer N, Mayfield J, Jones W, Allen D, Storzbach D, Demadura T, Tun S, Sutton G, Ringdahl E, Thaler N, Barney S, Mayfield J, Pinegar J, Allen D, Terranova J, Kazakov D, McMurray J, Mayfield J, Allen D, Villemure R, Nolin P, Le Sage N, Yeung E, Zakzanis K, Gammada E, Jeffay E, Yi A, Small S, Macciocchi S, Barlow K, Seel R, Rabinowitz A, Arnett P, Rabinowitz A, Barwick F, Arnett P, Bailey T, Brown M, Whiteside D, Waters D, Golden C, Grzybkowska A, Wyczesany M, Katz L, Brown F, Roth R, McNeil K, Vroman L, Semrud-Clikeman T, Terrie, Seydel K, Holster J, Corsun-Ascher C, Golden C, Holster J, Corsun-Ascher C, Golden C, Bolanos J, Bergman B, Rodriguez M, Patel F, Frisch D, Golden C, Brooks B, Holdnack J, Iverson G, Brown M, Lowry N, Whiteside D, Bailey T, Dougherty M, West S, Golden C, Estes B, Bell C, Hertza J, Dennison A, Jones K, Holster J, Caorsun-Ascher C, Armstrong C, Golden C, Mackelprang J, Karle J, Najmabadi S, Valley-Gray S, Cash R, Gonzalez E, Metoyer K, Holster J, Golden C, Natta L, Gomez R, Trettin L, Tennakoon L, Schatzberg A, Keller J, Davis J, Sherer C, Wall J, Ramos C, Patterson C, Shaneyfelt K, DenBoer J, Hall S, Gunner J, Miele A, Lynch J, McCaffrey R, Lo T, Cottingham M, Aretsen T, Boone K, Goldberg H, Miele A, Gunner J, Lynch J, McCaffrey R, Miele A, Benigno A, Gunner J, Leigh K, Lynch J, Drexler M, McCaffrey R, Weiss E, Ploetz D, Rohling M, Lankey M, Womble M, Yeung S, Silverberg N, Zakzanis K, Amirthavasagam S, Jeffay E, Gammada E, Yeung E, McDonald K, Constantinou M, DenBoer J, Hall S, Lee S, Klaver J, Kibby M, Stern S, Morris M, Morris R, Whittington L, Nemeth D, Olivier T, May N, Hamilton J, Steger A, Chan R, West S, Golden C, Landstrom M, Dodzik P, Boneff T, Williams T, Robbins J, Martin P, Prinzi L, Golden C, Barber B, Mucci G, Brzinski B, Frish D, Rosen S, Golden C, Hamilton J, Nemeth D, Martinez A, Kirk J, Exalona A, Wicker N, Green C, Broshek D, Kao G, Kirkwood M, Quigg M, Cohen M, Riccio C, Olson K, Rice J, Dougherty M, Golden C, Sharma V, Rodriguez M, Golden C, Paltin I, Walsh K, Rosenbaum K, Copenheaver D, Zand D, Kardel P, Acosta M, Packer R, Vasserman M, Fonseca F, Tourgeman I, Stack M, Demsky Y, Golden C, Horwitz J, McCaffey R, Ojeda C, Kadushin F, Wingler I, Lazarus G, Green J, Barth J, Puente A, Parikh M, Graham L, Hynan L, Grosch M, Weiner M, Cullum C, Tourgeman I, Bure-Reyes A, Stewart J, Stack M, Demsky Y, Golden C, Zhang J, Tourgeman I, Demsky Y, Stack M, Golden C, Bures-Reye A, Stewart J, Tourgeman I, Demsky Y, Stack M, Golden C, Finlay L, Goldberg H, Arentsen T, Lo T, Moriarti T, Mackelprang J, Karle J, Aragon P, Gonzalez E, Valley-Gray S, Cash R, Mackelprang J, Karle J, Hardie R, Cash R, Gonzalez E, Valley-Gray S, Mason J, Keller J, Gomez R, Trettin L, Schatzberg A, Moore R, Mausbach B, Viglione D, Patterson T, Morrow J, Barber B, Restrepo L, Mucci G, Golden C, Buchbinder D, Chang R, Wang R, Pearlson J, Scarisbrick D, Rodriguez M, Golden C, Restrepo L, Morrow J, Golden C, Switalska J, Torres I, DeFreitas C, DeFreitas V, Bond D, Yatham L, Zakzanis K, Gammada E, Jeffay E, Yeung E, Amirathavasagam S, McDonald K, Hertza J, Bell C, Estes B, Schiff W, Bayless J, McCormick L, Long J, Brumm M, Lewis J, Benigno A, Leigh K, Drexler M, Weiss E, Bharadia V, Walker L, Freedman M, Atkins H, Jackson A, Perna R, Cooper D, Lau D, Lyons H, Culotta V, Griffith K, Coiro M, Papadakis A, Weden S, Sestito N, Brennan L, Benjamin T, Ciaudelli B, Fanning M, Giovannetti T, Chute D, Vathhauer K, Steh B, Osuji J, Steh B, Katz D, Ackerman M, Vance D, Fazeli P, Ross L, Strang J, Strauss A, Bienia K, Hollingsworth D, Ensley M, Atkins J, Grigorovich A, Bell C, Fish J, Hertza J, Leach L, Schiff W, Gomez M, Estes B, Dennison A, Davis A, Roberds E, Lutz J, Byerley A, Mazur-Mosiewicz A, Davis M, Sutton S, Moses J, Doan B, Hanna M, Adam G, Wile A, Butler M, Self B, Heaton K, Brininger T, Edwards M, Johnson K, O'Bryan S, Williams J, Joes K, Frazier D, Moses J, Giesbrecht C, Nielson H, Barone C, Thornton A, Vila-Rodriguez F, Paquet F, Barr A, Vertinsky T, Lang D, Honer W, Hart J, Lavach J, Hietpas-Wilson T, Pella R, McCoy K, VanBuren K, Hilsabeck R, James S, Robillard R, Holder C, Long M, Sandhu K, Padua M, Moses J, Lutz J, Mazur-Mosiewicz A, Dean R, Olivier T, Nemeth D, Whittington L, May N, Hamilton J, Steger A, Roberg B, Hancock L, Jacobson J, Tyrer J, Lynch S, Bruce J, Sordahl J, Hertza J, Bell C, Estes B, Schiff W, Sousa J, Jerram M, Wiebe-Moore D, Susmaras T, Gansler D, Vertinski M, Smith L, Thaler N, Mayfield J, Allen D, Buscher L, Jared B, Hancock L, Roberg B, Tyrer J, Lynch S, Choi W, Lai S, Lau E, Li A, Covassin T, Elbin R, Kontos A, Larson E, Hubley A, Lazarus G, Puente A, Ojeda C, Mazur-Mosiewicz A, Trammell B, Dean R, Patwardhan S, Fitzgerald K, Meyers C, Wefel J, Poole J, Gray M, Utley J, Lew H, Riordan P, Sawyer J, Buscemi J, Lombardo T, Barney S, Allen D, Stolberg P, Mayfield J, Brown S, Tussey C, Barrow M, Marcopulos B, Kingma J, Heinly M, Fazio R, Griswold S, Denney R, Corney P, Crossley M, Edwards M, O'Bryant S, Hobson V, Hall J, Barber R, Zhang S, Johnson L, Diaz-Arrastia R, Hall J, Johnson L, Barber R, Cullum M, Lacritz L, O'Bryant S, Lena P, Robbins J, Martin P, Stewart J, Golden C, Martin P, Prinzi L, Robbins J, Golden C, Ruchinskas R, West S, Fonseca F, Rice J, McCue R, Golden C, Fischer A, Yeung S, Thornton W, Rossetti H, Bernardo K, Weiner M, Cullum C, Lacritz L, Yeung S, Fischer A, Thornton W, Zec R, Kohlrus S, Fritz S, Robbs R, Ala T, Cummings T, Webbe F, Srinivasan V, Gavett B, Kowall N, Qiu W, Jefferson A, Green R, Stern R, Hill B, Su T, Correia S, O'Bryant S, Gong G, Spallholz J, Boylan M, Edwards M, Hargrave K, Johnson L, Stewart J, Golden C, Broennimann A, Wisniewski A, Austin B, Bens M, Carroll C, Knee K, Mittenberg W, Zimmerman A, Mazur-Mosiewicz A, Roberds E, Dean R, Anderson C, Parmenter B, Blackwell E, Silverberg N, Douglas K, Gassermar M, Kranzler H, Chan G, Gelenter J, Arias A, Farrer L, Giummarra J, Bowden S, Cook M, Murphy M, Hancock L, Bruce J, Peterson S, Tyrer J, Murphy M, Jacobson J, Lynch S, Holder C, Mauseth T, Robillard R, Langill M, Roberts R, Iverson G, Appel-Cresswell S, Stoessl A, Macleod L, Bowden S, Partridge R, Webster B, Heinrichs R, Baade L, Sandhu K, Padua M, Long M, Moses J, Schmitt A, Werry A, Hu S, Stewart R, Livingston R, Deitrick S, Doyle K, Smernoff E, Schoenberg M, Rinehardt E, Mattingly M, Borzog A, Rodgers-Neame N, Vale F, Frontera A, Benbadis S, Ukueberuwa D, Arnett P, Vargas G, Riordan P, Arnett P, Lipinski D, Sawyer J, Brewer V, Viner K, Lee G, Walker L, Berrigan L, Ress L, Cheng A, Freedma M, Hellings J, Whiteside D, Brown J, Singer R, Woods S, Weber E, Cameron M, Dawson M, Grant I, Frisch D, Brzinski B, Golden C, Hutton J, Vidal O, Puente A, Klaver J, Lee S, Kibby M, Mireles G, Anderson B, Davis J, Rosen S, Scarisbrick D, Brzinski B, Golden C, Simek A, Vaughn C, Wahlberg A, Yoon H, Riccio C, Steger A, Nemeth D, Thorgusen S, Suchy Y, Rau H, Williams P, Wahlberg A, Yoon V, Simek A, Vaughn C, Riccio C, Whitman L, Bender H, Granader Y, Freshman A, MacAllister W, Freshman A, Bender H, Whitman L, Granader Y, MacAllister W, Yoon V, Simek A, Vaughn C, Wahlberg A, Riccio C, Noll K, Cullum C, O'Bryant S, Hall J, Simpson C, Padua M, Long M, Sandhu K, Moses J, Scarisbrick D, Holster J, Corsun-Ascher C, Golden C, Stang B, Trettin L, Rogers E, Saleh M, Che A, Tennakoon L, Keller J, Schatzberg A, Gomez R, Tayim F, Moses J, Morris R, Thaler N, Lechuga D, Cross C, Salinas C, Reynolds C, Mayfield J, Allen D, Webster B, Partridge R, Heinrichs R, Badde L, Weiss E, Antoniello D, McGinley J, Gomes W, Masur D, Brooks B, Holdnack J, Iverson G, Banville F, Nolin P, Henry M, Lalonde S, Dery M, Cloutier J, Green J, Sokol D, Lowery K, Hole M, Helmus A, Teat R, DelMastro C, Paquette B, Grosch M, Hynan L, Graham L, Parikh M, Weiner M, Cullum M, Hubley A, Lutz J, Dean R, Paterson T, O'Rourke N, Thornton W, Randolph J, Suffiield J, Crockett D, Spreen O, Trammell B, Mazur-Mosiewicz A, Holcomb M, Dean R, Busse M, Wald D, Whiteside D, Breisch A, Fieldstone S, Vannorsda T, Lassen-Greene C, Gordon B, Schretlen D, Launeanu M, Hubley A, Maruyama R, Cuesta G, Davis J, Takahashi T, Shinoda H, Gregg N, Davis J, Cheung S, Takahashi T, Shinoda H, Gregg N, Holcomb M, Mazur A, Trammell B, Dean R, Perna R, Jackson A, Villar R, Ager D, Ellicon B, Als L, Nadel S, Cooper M, Pierce C, Hau S, Vezir S, Picouto M, Sahakian B, Garralda E, Mucci G, Barber B, Semrud-Clikeman M, Goldenring J, Bledsoe J, Vroman L, Crow S, Zimmerman A, Mazur-Mosiewicz A, Roberds E, Dean R, Sokol D, Hole M, Teat R, Paquett B, Albano J, Broshek D, Elias J, Brennan L, Chakravarti P, Schultheis L, Kibby M, Weisser V, Hynd G, Ang J, Crockett D, Puente A, Weiss E, Longman R, Antoniello D, Axelrod B, McGinley J, Gomes W, Masur D, Davis A, Lutz J, Roberds E, Williams R, Gupta A, Estes B, Dennison A, Schiff W, Hertza J, Ferrari M. Grand Rounds. Arch Clin Neuropsychol 2010. [DOI: 10.1093/arclin/acq056] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
200
|
Malhotra H, Patil S, Wang Z, Johnson K, Lele S, Odunsi K, DuPont N, Yap J. SU-GG-T-59: Optimization of the Applicator Position in the Treatment of Vaginal Vault HDR Brachytherapy: A Study Based on GEC-ESTRO Guidelines. Med Phys 2010. [DOI: 10.1118/1.3468445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|